Erratum for Kris et al., J Clin Oncol 24 (18) 2932-2947.

This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content

ERRATUM

In Section I, "Emesis Caused By Intravenously Administered Antineoplastic Agents," the headings under Subsection A, "Vomiting Occurring 0 To 24 Hours After Therapy (Acute Emesis)" should have been numbered as follows:

1. Emetic Risk of Antineoplastic Agents: Emetic Risk Categories
   
2. Antiemetic Agents: Highest Therapeutic Index
   
3. Antiemetic Agents: Lower Therapeutic Index—Metoclopramide, Butyrophenones, Phenothiazines, and Cannabinoids
   
4. Antiemetic Agents: Adjunctive Drugs (benzodiazepines [lorazepam, alprazolam] and antihistamines [diphenhydramine])
   
5. Antiemetic Agents: Combinations of Antiemetics
   
6. Recommendations for Specific Emetic Risk Categories
   

In ^{Table 7}, under "Antiemetic Regimens and Schedules," Dexamethasone was scheduled on days 1, 2 and 3 for "High" emetic risk, and should have been given on days 1-4. Also, Dexamethasone was scheduled on day 1 only for "Moderate" emetic risk, and should have been listed as continuing on days 2 and 3 when aprepitant is not given. The corrected table is reprinted below in its entirety.

In ^{Table 8}, under "Single Dose Administered Before Chemotherapy," "Oral: 12 mg (with aprepitant)" and "Oral: 20 mg" were listed for Dexamethasone, while it should have read, "Oral: 12 mg" only. Under "Single Dose Administered Daily," "Oral: 8 mg days 2, 3" was listed for Dexamethasone, while it should have read, "Oral: 8 mg days 2-4." Also, "Dexamethasone" should have been left-justified as a row heading. The corrected table is reprinted below in its entirety.

On page 2937, the second sentence of the last paragraph was given as: "In the trials in patients receiving cisplatin, dexamethasone was also administered at a reduced dosage of 8 mg once daily on days 2 and 3.^33,34"

While it should have read:

"In the trials in patients receiving cisplatin, dexamethasone was also administered at a reduced dosage of 8 mg once daily on days 2 to 4.^33,34"

In Table 9, under "Dexamethasone," both 8 mg doses should have been listed as "without aprepitant."

On page 2938, the second sentence of the second to last paragraph was given as: "Overall, vomiting prevention was improved by 9% (P = .015) for the 5-day period after chemotherapy with the three-drug regimen of aprepitant, ondansetron, and dexamethasone, over the standard combination of ondansetron and dexamethasone alone."

While it should have read:

"Complete response was improved by 9% (P = .015) for the 5-day period after chemotherapy with the three-drug regimen of aprepitant, ondansetron, and dexamethasone, over the standard combination of ondansetron and dexamethasone alone.^39"

Also on page 2938, the second to last sentence of the last paragraph was given as:

"The Panel cautions that the recommendation to use a lower dose of dexamethasone when administered as an antiemetic with aprepitant does not apply to the use of prednisone, dexamethasone, or any corticosteroid when administered as an anticancer therapy (ie, as part of cyclophosphamide, doxorubicin, vincristine, prednisone [CHOP] or cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy regimens)."

While it should have read:

"The Panel cautions that the recommendation to use a lower dose of dexamethasone when administered as an antiemetic with aprepitant does not apply to the use of prednisone, dexamethasone, or any corticosteroid when administered as an anticancer therapy (ie, as part of cyclophosphamide, doxorubicin, vincristine, prednisone [CHOP]-based or mechlorethamine, vincristine, procarbazine, and prednisone [MOPP] chemotherapy regimens)."

The online version has been corrected in departure from the print.

This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content